Novartis Combo On Track To Be First Targeted BRAF NSCLC Therapy
Executive Summary
The EU's CHMP has granted a positive opinion for Novartis' combo of MEK inhibitor Mekinist and BRAF inhibitor Tafinlar for BRAF-positive non-small cell lung cancer patients.
You may also be interested in...
Novartis' Growth Driver Tafinlar/Mekinist Picks Up New Melanoma, Thyroid Indications
New FDA labeling brings Tafinlar/Mekinist into adjuvant melanoma setting, but Bristol's competing Opdivo already has captured nearly 50% of the market and is approved regardless of genetic mutation.
Ex-GSK Melanoma Therapy Secures EU Approval For Novartis
Novartis AG has been granted European approval for two products it picked up via a $20bn mega deal transaction with GlaxoSmithKline plc, a deal which closed in March this year.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.